關口前移,聯防聯控,嚴防人獸共患病

夏咸柱

引用本文: 夏咸柱. 關口前移,聯防聯控,嚴防人獸共患病[J]. 疾病監測. DOI: 10.3784/j.issn.1003-9961.2019.10.005 shu
Citation:  Xianzhu XiaPut forward the checkpoint, joint the prevention and control, and take strict preventive measures against zoonoses[J]. Disease Surveillance. DOI: 10.3784/j.issn.1003-9961.2019.10.005 shu

關口前移,聯防聯控,嚴防人獸共患病

    作者簡介: 夏咸柱,男,江蘇省建湖市人,中國工程院院士,主要從事動物傳染病與人獸共患病的防控研究工作;
    通信作者: 夏咸柱, [email protected]
  • 基金項目: 國家重點研發計劃(2016YFD0501004)

摘要: 人獸共患病種類繁多,流行趨勢復雜,狂犬病、結核病、布魯氏菌病等原有人獸共患病不斷連發、再發,禽流感、嚴重急性呼吸窘迫綜合征(SARS)、中東呼吸綜合征(MERS)等新發人獸共患病接連出現,而隨著全球交流日益增多,埃博拉出血熱、MERS、瘋牛病、亨–尼帕腦炎、西尼羅病毒病、裂谷熱、寨卡病毒病、黃熱病等外來人獸共患病則威脅不斷。 人獸共患病在世界范圍內形勢嚴峻,關系重大,其防控不僅事關國家全局,還關系到健康養殖、食品安全、公共衛生安全、國家生物安全以及社會的和諧穩定。 針對不同人獸共患病,政府和科研機構要加強研究,科學防控,建立優化各種病原體的檢測方法,研發制備行之有效的疫苗和藥物,完善機制,聯防聯控,努力建立協同聯動機制共同預防應對重大傳染病疫情的發生和發展。

English

    1. [1]

      薛康寧, 劉曉宇, 榮蓉, 等. 我國主要新發與再發人獸共患病相關介紹[J]. 中國人獸共患病學報,2016,32(3):290–294. DOI:10.3969/j.issn.1002?2694.2016.03.016.
      Xue KN, Liu XY, Rong R, et al. Introduction of emerging and reemerging zoonoses in China[J]. Chin J Zoonoses, 2016,32(3):290–294. DOI:10.3969/j.issn.1002?2694.2016.03.016.

    2. [2]

      Yuen KY, Chan PKS, Peiris M, et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus[J]. Lancet, 1998,351(9101):467–471. DOI:10.1016/S0140?6736(98)01182?9.

    3. [3]

      Ye CY, Bai XM, Zhang J, et al. Spread of Streptococcus suis sequence type 7, China[J]. Emerg Infect Dis, 2008,14(5):787–791. DOI:10.3201/eid1405.070437.

    4. [4]

      Guan Y, Zheng BJ, He YQ, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China[J]. Science, 2003,302(5643):276–278. DOI:10.1126/science.1087139.

    5. [5]

      van den Brand JM, Smits SL, Haagmans BL. Pathogenesis of Middle East respiratory syndrome coronavirus[J]. J Pathol, 2015,235(2):175–184. DOI:10.1002/path.4458.

    6. [6]

      Li Q, Zhou L, Zhou MH, et al. Epidemiology of human infections with avian influenza A(H7N9) virus in China[J]. N Engl J Med, 2014,370(6):520–532. DOI:10.1056/NEJMoa1304617.

    7. [7]

      夏咸柱, 高宏偉, 華育平. 野生動物疫病學[M]. 北京: 高等教育出版社, 2011: 190–906.
      Xia XZ, Gao HW, Hua YP. Zoology of wild animals[M]. Beijing: Higher education Press, 2011: 190–906.

    8. [8]

      Casals J. Antigenic similarity between the virus causing Crimean hemorrhagic fever and Congo virus[J]. Proc Soc Exp Biol Med, 1969,131(1):233–236. DOI:10.3181/00379727?131?33847.

    9. [9]

      Cao L, Fu SH, Lu Z, et al. Detection of West Nile virus infection in viral encephalitis Cases, China[J]. Vector Borne Zoonotic Dis, 2019,19(1):45–50. DOI:10.1089/vbz.2018.2275.

    10. [10]

      Cao L, Fu SH, Lv Z, et al. West Nile virus infection in suspected febrile typhoid cases in Xinjiang, China[J]. Emerg Microbes Infect, 2017,6(6):e41. DOI:10.1038/emi.2017.27.

    11. [11]

      Daubney R, Hudson JR, Garnham PC. Enzootic hepatitis or Rift Valley fever. An undescribed virus disease of sheep cattle and man from East Africa[J]. J Pathol Bacteriol, 1931,34(4):545–579. DOI:10.1002/path.1700340418.

    12. [12]

      Shi YX, Zheng K, Li XB, et al. Isolation and phylogenetic study of Rift Valley fever virus from the first imported case to China[J]. Virol Sin, 2017,32(3):253–256. DOI:10.1007/s12250?017?3949?z.

    13. [13]

      Liu JY, Sun YL, Shi WF, et al. The first imported case of Rift Valley fever in China reveals a genetic reassortment of different viral lineages[J]. Emerg Microbes Infect, 2017,6(1):e4. DOI:10.1038/emi.2016.136.

    14. [14]

      劉曉青, 謝春燕, 楊富強, 等. 中國大陸首例輸入性寨卡病毒感染病例風險評估[J]. 中華疾病控制雜志,2016,20(5):527–529. DOI:10.16462/j.cnki.zhjbkz.2016.05.024.
      Liu XQ, Xie CY, Yang FQ, et al. Risk assessments for the first imported Zika virus infections in mainland China[J]. Chin J Dis Control Prev, 2016,20(5):527–529. DOI:10.16462/j.cnki.zhjbkz.2016.05.024.

    15. [15]

      Wilder-Smith A, Leong WY. Importation of yellow fever into China: assessing travel patterns[J]. J Travel Med, 2017,24(4). DOI:10.1093/jtm/tax008.

    16. [16]

      中國養殖業可持續發展戰略研究項目組. 中國工程院重大咨詢項目《中國養殖業可持續發展戰略研究(綜合卷)》[M]. 北京: 中國農業出版社, 2013: 35.
      Sustainable Development Strategy Project Team of Aquaculture Industry in China. Major consulting projects of Chinese Academy of Engineering, Research on sustainable development strategy of aquaculture industry in China (Comprehensive volume)[M]. Beijing: China Agriculture Press, 2013: 35.

    17. [17]

      夏咸柱, 錢軍, 劉文森. 中國工程院重點咨詢項目《食品安全與病原微生物防控研究》[M]. 北京: 科學出版社, 2016: 4.
      Xia XZ, Qian J, Liu WS. Major consulting projects of Chinese Academy of Engineering, Food safety and control of marginal microorganisms[M]. Beijing: Science Press, 2016: 4.

    18. [18]

      夏咸柱, 錢軍, 劉文森, 等. 食品安全與病原微生物防控研究[M]. 北京: 科學出版社, 2017: 1–30.
      Xia XZ, Qian J, Liu WS, et al. Food safety and control of pathogenic microorganisms[M]. Beijing: Science Press, 2016: 1–30.

    19. [19]

      Qi YL, Kang HT, Zheng XX, et al. Incorporation of membrane-anchored flagellin or Escherichia coli heat-labile enterotoxin B subunit enhances the immunogenicity of rabies virus-like particles in mice and dogs[J]. Front Microbiol, 2015,6:169. DOI:10.3389/fmicb.2015.00169.

    20. [20]

      Kang HT, Qi YL, Wang HL, et al. Chimeric rabies virus-like particles containing membrane-anchored GM-CSF enhances the immune response against rabies virus[J]. Viruses, 2015,7(3):1134–1152. DOI:10.3390/v7031134.

    21. [21]

      Prevec L, Campbell JB, Christie BS, et al. A recombinant human adenovirus vaccine against rabies[J]. J Infect Dis, 1990,161(1):27–30. DOI:10.1093/infdis/161.1.27.

    22. [22]

      蓋微微, 鄭學星, 薛向紅, 等. 埃博拉病毒檢測與分型Real-time PCR方法的建立[J]. 中國病原生物學雜志,2013,8(3):208–211, 216. DOI:10.13350/j.cjpb.2013.03.001.
      Gai WW, Zheng XX, Xue XH, et al. Development of a real-time PCR method to detect and type Ebola virus[J]. J Parasit Biol, 2013,8(3):208–211, 216. DOI:10.13350/j.cjpb.2013.03.001.

    23. [23]

      Xu CP, Wang HL, Jin HL, et al. Visual detection of Ebola virus using reverse transcription loop-mediated isothermal amplification combined with nucleic acid strip detection[J]. Arch Virol, 2016,161(5):1125–1133. DOI:10.1007/s00705?016?2763?5.

    24. [24]

      Zhu FC, Hou LH, Li JX, et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial[J]. Lancet, 2015,385(9984):2272–2279. DOI:10.1016/S0140?6736(15)60553?0.

    25. [25]

      Butler D, Callaway E, Check Hayden E. How Ebola-vaccine success could reshape clinical-trial policy[J]. Nature, 2015,524(7563):13–14. DOI:10.1038/524013a.

    26. [26]

      Zheng XX, Wong G, Zhao YK, et al. Treatment with hyperimmune equine immunoglobulin or immunoglobulin fragments completely protects rodents from Ebola virus infection[J]. Sci Rep, 2016,6:24179. DOI:10.1038/srep24179.

    27. [27]

      Wang HL, Wong G, Zhu WJ, et al. Equine-origin immunoglobulin fragments protect nonhuman primates from Ebola virus disease[J]. J Virol, 2019,93(5):e01548–18. DOI:10.1128/JVI.01548-18.

    28. [28]

      Wang C, Zheng XX, Gai WW, et al. MERS-CoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques[J]. Oncotarget, 2017,8(8):12686–12694. DOI:10.18632/oncotarget.8475.

    29. [29]

      Chi H, Zheng XX, Wang XW, et al. DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice[J]. Vaccine, 2017,35(16):2069–2075. DOI:10.1016/j.vaccine.2017.02.063.

    30. [30]

      Zhao YK, Wang C, Qiu BN, et al. Passive immunotherapy for Middle East respiratory syndrome coronavirus infection with equine immunoglobulin or immunoglobulin fragments in a mouse model[J]. Antiviral Res, 2017,137:125–130. DOI:10.1016/j.antiviral.2016.11.016.

    31. [31]

      Qiu HJ, Sun SH, Xiao H, et al. Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection[J]. Antiviral Res, 2016,132:141–148. DOI:10.1016/j.antiviral.2016.06.003.

    32. [32]

      Jiang LW, Wang NS, Zuo T, et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein[J]. Sci Transl Med, 2014,6(234):234ra259. DOI:10.1126/scitranslmed.3008140.

    33. [33]

      Ying TL, Du LY, Ju TW, et al. Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies[J]. J Virol, 2014,88(14):7796–7805. DOI:10.1128/JVI.00912?14.

    34. [34]

      Zhao GY, He L, Sun SH, et al. A novel nanobody targeting middle east respiratory syndrome coronavirus (MERS-CoV) receptor-binding domain has potent cross-neutralizing activity and protective efficacy against MERS-CoV[J]. J Virol, 2018,92(18):e00837–18. DOI:10.1128/JVI.00837?18.

    35. [35]

      Li YT, Wang CL, Zheng XX, et al. Development and characterization of Rift Valley fever virus-like particles[J]. Genet Mol Res, 2016,15(1):gmr.15017772. DOI:10.4238/gmr.15017772.

    36. [36]

      Zhao YK, Zheng XX, He SH, et al. Equine immunoglobulin F(ab')2 fragments protect mice from Rift Valley fever virus infection[J]. Int Immunopharmacol, 2018,64:217–222. DOI:10.1016/j.intimp.2018.09.002.

    1. [1]

      龔震宇龔訓良 . 2014年全球寄生蟲病預防性化療的進展情況. 疾病監測, 2016, 31(9): 799-800. DOI: 10.3784/j.issn.1003-9961.2016.09.020

    2. [2]

      龔震宇龔訓良 . 2014年1月至2015年4月全球人感染來源于動物流感病毒病例的防控概況. 疾病監測, 2016, 31(1): 85-88. DOI: 10.3784/j.issn.1003-9961.2016.01.021

    3. [3]

      馬潔瓊栗冬梅陳忠科劉起勇 . 鼠傳巴爾通體流行概況. 疾病監測, 2018, 33(1): 7-14. DOI: 10.3784/j.issn.1003-9961.2018.01.004

    4. [4]

      龔震宇(摘譯)楊小平(審校) . 全球麻疹控制的進展情況. 疾病監測, 2012, 27(6): 503-504. DOI: 10.3784/j.issn.1003-9961.2012.6.025

    5. [5]

      崔長弘 . 帶狀皰疹流行病學特征及預防策略研究現狀. 疾病監測, 2013, 28(12): 1030-1034. DOI: 10.3784/j.issn.1003-9961.2013.12.019

    6. [6]

      龔震宇(摘譯)龔訓良(審校) . 美國1938-2018年人類狂犬病暴露和死亡的趨勢分析. 疾病監測, 2019, 34(10): 953-954. DOI: 10.3784/j.issn.1003-9961.2019.10.020

    7. [7]

      郭舫茹吳勁楊咸枝楊娜李敏 . 2012年北京市石景山區疑似預防接種異常反應監測分析. 疾病監測, 2014, 29(1): 62-65. DOI: 10.3784/j.issn.1003-9961.2014.01.017

    8. [8]

      . 2010-2013年新疆克拉瑪依市疑似預防接種異常反應監測系統運轉情況及監測結果分析. 疾病監測, 2015, 30(1): 71-74. DOI: 10.3784/j.issn.1003-9961.2015.01.018

    9. [9]

      龔震宇龔訓良 . WHO關于登革熱疫苗的意見書(摘要)(2016年7月). 疾病監測, 2016, 31(12): 1076-1078. DOI: 10.3784/j.issn.1003-9961.2016.12.022

    10. [10]

      龔震宇楊小平 . WHO關于腦膜炎球菌疫苗的意見書. 疾病監測, 2012, 27(3): 248-252.

    11. [11]

      吳承剛疏俊韓軻譚秋林嘉子 . 不同風疹疫苗接種策略對廣東省風疹流行的影響. 疾病監測, 2012, 27(2): 110-113.

    12. [12]

      徐一文陳怡平王連華鄭翔邱春華 . 浙江省臺州市2017年國家免疫規劃疫苗接種數據分析. 疾病監測, 2019, 34(1): 84-88. DOI: 10.3784/j.issn.1003-9961.2019.01.020

    13. [13]

      韓敘劉東磊 . 國產與進口流行性腮腺炎疫苗免疫后陽轉率的Meta分析. 疾病監測, 2013, 28(4): 288-293. DOI: 10.3784/j.issn.1003-9961.2013.4.011

    14. [14]

      龔甫哲(摘譯)龔震宇(審校) . 2018年9月世界衛生組織關于登革熱疫苗的意見書. 疾病監測, 2019, 34(3): 278-284. DOI: 10.3784/j.issn.1003-9961.2019.03.020

    15. [15]

      張恩民湛志飛魏強張錫興胡艷紅夏昕萬康林魏建春高立冬 . 一起疑似炭疽疫苗菌株毒力恢復事件中炭疽芽孢桿菌的毒力鑒定與分析. 疾病監測, 2019, 34(1): 76-79. DOI: 10.3784/j.issn.1003-9961.2019.01.018

    16. [16]

      龔震宇楊小平 . 世界衛生組織關于狂犬病疫苗的意見書. 疾病監測, 2012, 27(2): 166-168.

    17. [17]

      胡雅飛林海江李未 . 2劑水痘疫苗接種程序對浙江省臺州市水痘流行特征的影響. 疾病監測, 2019, 34(10): 916-919. DOI: 10.3784/j.issn.1003-9961.2019.10.012

  • 加載中
計量
  • PDF下載量:  14
  • 文章訪問數:  317
  • HTML全文瀏覽量:  119
  • 引證文獻數: 0
文章相關
  • 通信作者:  夏咸柱, [email protected]
  • 收稿日期:  2019-09-27
  • 網絡出版日期:  2019-10-24
  • 刊出日期:  2019-10-01
通信作者: 陳斌, [email protected]
  • 1. 

    沈陽化工大學材料科學與工程學院 沈陽 110142

  1. 本站搜索
  2. 百度學術搜索
  3. 萬方數據庫搜索
  4. CNKI搜索

/

返回文章

在線交流

广西体彩11选五开奖